^
    Back
    Association details:
    Biomarker:CDCA3 overexpression
    Cancer:Non Small Cell Lung Cancer
    Drug:cisplatin (DNA synthesis inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Commun Biol
    Title:

    Elevating CDCA3 levels in non-small cell lung cancer enhances sensitivity to platinum-based chemotherapy

    Published date:
    05/28/2021
    Excerpt:
    Patients with NSCLC may undergo adjuvant chemotherapy for resectable disease...in patients and in vitro analyses, CDCA3 levels correlate with measures of genome instability and platinum sensitivity, whereby CDCA3 high tumours are sensitive to cisplatin and carboplatin.
    DOI:
    https://doi.org/10.1038/s42003-021-02136-8